PTC Therapeutics director Michael Schmertzler sells $158k in shares

PTC Therapeutics director Michael Schmertzler sold $158,480 worth of the company's common stock on October 7, 2026, according to wire material. The shares were sold at prices between $63.38 and $63.95 per share. The stock is currently trading around $64.70, close to its 52-week low of $61.23, and down nearly 15% year-to-date. Mr. Schmertzler is a general and limited partner in Section Six Partners, L.P., where the sales were conducted.

He disclaims beneficial ownership of the shares held by the partnership, except for his financial interest. This insider sale took place pursuant to a Rule 10b5-1 trading plan adopted by Section Six Partners, L.P. on May 14, 2026. PTC Therapeutics, with a market capitalization of $5.37 billion, is set to release earnings on October 22.

Analysts have a cautiously optimistic view, with price targets ranging from $70 to $137. The company reported strong Q2 2026 earnings of $0.92 per share on $361 million in revenue, exceeding expectations. PTC Therapeutics also acquired gene therapy ST-920 from Sangamo and raised its full-year revenue outlook. The company's cash reserves of $2.23 billion have enabled it to pursue further transactions.

Biotech funding has increased by 75% year-over-year, providing a favorable environment for the sector.